Actively Recruiting
Tumor Cell and DNA Detection in Peripheral Blood of Patients With Hematological Malignancy
Led by University of Missouri-Columbia · Updated on 2025-12-10
50
Participants Needed
1
Research Sites
N/A
Total Duration
On this page
AI-Summary
What this Trial Is About
This research aims to better understand the role of Dipeptidyl Peptidase-4 (DPP4) inhibitors in treating acute myeloid leukemia (AML) and other blood cancers. AML is a serious blood cancer responsible for a large number of deaths each year in the United States, and new treatments are needed. The study focuses on how DPP4 is involved in leukemia and other blood malignancies, hoping to improve personalized therapies. The study involves collecting blood and bone marrow samples from patients with various blood cancers. Researchers will analyze these samples to investigate the effect of DPP4 inhibitors on leukemia stem cells both in laboratory tests and living organisms. The study also explores whether DPP4 inhibitors can help prevent AML from coming back once it is in remission. Participants will provide blood and bone marrow samples during clinic visits or hospital stays. Researchers will monitor DPP4 inhibitor levels in blood and correlate these with patient survival over five years. The study will include laboratory tests and data collection to understand how DPP4 impacts leukemia progression. This observational study does not involve treatment but focuses on analyzing samples and survival data over time.
CONDITIONS
Brief Title
Membrane Target Detection for Leukemia Treatment
Who Can Participate
Eligibility Criteria
You may qualify if you...
- All hematological malignancy patients.
- Must be 18 years old or older.
You will not qualify if you...
- Participants with impaired decision-making capacities.
- Pregnant women or fetuses.
- Children under 18 years old.
- Non-viable neonates or neonates of uncertain viability.
- Non-English-speaking subjects.
- Prisoners.
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Your Study Journey
Duration - 2 to 4 weeks
Participants are screened for eligibility to participate in the trial.
1 visit (in-person)
Duration - Up to 5 years
Participants provide peripheral blood and bone marrow samples during clinic visits and hospital stays to help researchers investigate the role of DPP4 in hematological malignancies.
Periodic clinic visits and hospital stays as needed for sample collection
Duration - Up to 5 years
Participants are monitored over time to correlate DPP4 inhibitor levels in blood samples with survival data.
Follow-up visits as scheduled for monitoring
Trial Site Locations
Total: 1 location
1
University of Missouri
Columbia, Missouri, United States, 65212
Actively Recruiting
Research Team
X
Xunlei Kang, MD.PhD
How is the study designed?
Study Type
OBSERVATIONAL
Masking
N/A
Allocation
N/A
Model
N/A
Primary Purpose
N/A
Number of Arms
0
Similar Trials
Frequently Asked Questions
Have more questions? Get in touch with our team for quick support
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here